肥満：現在及び未来の競争環境分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 11
2 Introduction 12
2.1 Catalyst 13
2.2 Related Reports 14
2.3 Upcoming Related Reports 15
3 Market Outlook 16
3.1 Global Markets 17
3.1.1 Forecast 17
3.1.2 Drivers and Barriers – Global Issues 18
4 Current and Future Players 26
4.1 Overview 26
4.1.1 Medical Device Companies Have the Opportunity to Incorporate Lifestyle Programs 28
4.2 Trends in Corporate Strategy 31
4.3 Company Profiles: Pharmaceutical and Biotech Companies 32
4.3.1 Orexigen Therapeutics 32
4.3.2 Novo Nordisk 35
4.3.3 Takeda Pharmaceutical Company 37
4.3.4 Shionogi 39
4.3.5 Roche Holdings 40
4.3.6 Vivus 42
4.3.7 Arena Pharmaceuticals and Eisai 46
4.4 Company Profiles: Device Companies 49
4.4.1 Allergan 49
4.4.2 Apollo Endosurgery 51
4.4.3 Aspire Bariatrics 53
4.4.4 Agency for Medical Innovation 54
4.4.5 Bariatric Solutions 55
4.4.6 Baronova 56
4.4.7 BaroSense 57
4.4.8 BFKW 59
4.4.9 Cousin Biotech 60
4.4.10 C.R. Bard 61
4.4.11 Endalis Laboratory 62
4.4.12 EndoGastric Solutions 63
4.4.13 EndoSphere 64
4.4.14 EnteroMedics 65
4.4.15 Ethicon Endo-Surgery 67
4.4.16 GI Dynamics 68
4.4.17 Helioscopie 69
4.4.18 IntraPace 71
4.4.19 Medical Innovation Development 72
4.4.20 MetaCure 73
4.4.21 Obalon Therapeutics 74
4.4.22 ReShape Medical 76
4.4.23 Spatz Medical 77
4.4.24 ValenTx 78
5 Appendix 79
5.1 Bibliography 79
5.2 Abbreviations 82
5.3 Research Methodology 84
5.4 Forecasting Methodology 84
5.4.1 Percent Drug-Treated Obesity Patients 85
5.4.2 Drugs Included in Each Therapeutic Class 85
5.4.3 Launch and Patent Expiry Dates 86
5.4.4 General Pricing Assumptions 86
5.4.5 Individual Drug Assumptions 87
5.4.6 Generic Erosion 91
5.4.7 Pricing of Pipeline Agents 91
5.5 Physicians, Specialists, and Payers Included in This Study 92
5.6 About the Authors 95
5.6.1 Analysts 95
5.6.2 Therapy Director – CVMD and Infectious Disease 96
5.6.3 Director – Medical Devices 96
5.6.4 Global Head of Healthcare 97
5.7 About GlobalData 98
5.8 Disclaimer 98